← The Wire
PCRXNasdaq
Pacira BioSciences, Inc.
Pharmaceutical Preparations · DE · CIK 1396814
Pacira BioSciences delivers innovative, non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera°
red 8-K · 90d
$905M
Market cap
$25.09
Last close
-0.6%
1D
+10.5%
5D
392K
Volume
Price · last 39 sessions+1.6%
May 4L $22.25 · H $25.24Jun 29
262
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 11, 2026DEFA14ADEFA14AJun 4, 2026DEFA14ADEFA14AJun 1, 2026DEFA14ADEFA14AMay 28, 2026DEFA14ADEFA14AMay 27, 2026DEFA14ADEFA14AMay 26, 2026DEFA14ADEFA14AMay 20, 2026DEFA14ADEFA14AMay 20, 2026DEFA14ADEFA14AMay 13, 2026DEFA14ADEFA14AMay 12, 2026DEFA14ADEFA14AMay 5, 202610-Q10-K - PCRX - 03.31.2026Apr 30, 20268-KResults of OperationsApr 30, 2026DEFA14ADEFA14AApr 28, 2026SC 13D/ASC 13D/AMar 12, 2026DEFA14ADEFA14AMar 11, 202610-K10-K - PCRX - 12.31.2025Feb 26, 20268-KResults of OperationsFeb 26, 20268-KExecutive Change · Reg FD DisclosureJan 28, 20268-KResults of OperationsJan 8, 2026SC 13D/ASC 13D/AJan 2, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KExit / Disposal Costs · Reg FD DisclosureJul 10, 20258-KMaterial Agreement · Agreement TerminatedJul 7, 20258-KExecutive Change · Shareholder VoteJun 13, 202510-Q10-Q - PCRX - 3.31.2025May 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 20258-KCompany UpdateApr 22, 2025DEFA14ADEFA14AApr 18, 2025DEFA14ADEFA14AApr 17, 20258-KMaterial Agreement · Reg FD DisclosureApr 7, 20258-KBylaw AmendmentMar 14, 2025DEFA14ADEFA14AMar 14, 202510-K10-K - PCRX - 12.31.2024Feb 27, 20258-KResults of OperationsFeb 27, 20258-KExecutive Change · Reg FD DisclosureJan 30, 20258-KExecutive Change · Reg FD DisclosureJan 21, 20258-KResults of OperationsJan 10, 202510-Q10-Q - PCRX - 9.30.2024Nov 6, 20248-KExecutive Change · Results of OperationsNov 6, 20248-KExecutive Change · Reg FD DisclosureOct 21, 20248-KExecutive ChangeSep 27, 20248-KCompany UpdateSep 9, 20248-KCompany UpdateAug 9, 202410-Q10-QJul 30, 20248-KResults of OperationsJul 30, 20248-KExecutive Change · Shareholder VoteJun 13, 20248-KMaterial Agreement · New Debt / ObligationMay 14, 20248-KMaterial Agreement · New Debt / ObligationMay 8, 202410-Q10-Q - PCRX - 3.31.2024May 7, 20248-KResults of Operations · Company UpdateMay 7, 2024DEFA14ADEFA14AApr 22, 2024DEF 14ADEF 14AApr 22, 202410-K10-K - PCRX - 12.31.2023Feb 29, 20248-KExecutive Change · Results of OperationsFeb 29, 20248-KResults of OperationsJan 4, 20248-KExecutive Change · Reg FD DisclosureDec 21, 202310-Q10-Q - PCRX - 9.30.2023Nov 2, 20238-KResults of OperationsNov 2, 20238-KExecutive Change · Reg FD DisclosureOct 10, 20238-KExecutive Change · Reg FD DisclosureSep 26, 20238-KCompany UpdateSep 11, 202310-Q10-Q - PCRX - 6.30.2023Aug 2, 20238-KResults of OperationsAug 2, 20238-KExecutive Change · Shareholder VoteJun 20, 202310-Q10-Q - PCRX - 3.31.2023May 3, 20238-KResults of OperationsMay 3, 2023DEFA14ADEFA14AApr 21, 2023DEF 14AFORM DEF 14AApr 21, 20238-KMaterial Agreement · Agreement TerminatedApr 3, 20238-KExecutive Change · Reg FD DisclosureMar 22, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 20238-KResults of OperationsJan 5, 20238-KResults of OperationsDec 13, 2022
Insider Activity
In the 90 days to Mar 17, 2026: 4 sold $473K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Slonin JonathanChief Medical Officer | Sell | 3,261 | $22.82 | $74K |
| Mar 17, 2026 | Froimson MarkDirector | Sell | 500 | $21.81 | $11K |
| Feb 2, 2026 | Williams KristenChief Administrative Officer | Sell | 13,137 | $20.53 | $270K |
| Feb 2, 2026 | Riker LaurenSenior Vice President, Finance | Sell | 4,000 | $20.81 | $83K |
| Jan 5, 2026 | Riker LaurenSenior Vice President, Finance | Sell | 1,416 | $24.24 | $34K |
| Dec 10, 2025 | Cross ShawnChief Financial Officer | Sell | 9,104 | $25.14 | $229K |
| Dec 9, 2025 | Cross ShawnChief Financial Officer | Sell | 15,896 | $25.03 | $398K |
| Nov 17, 2025 | Slonin JonathanChief Medical Officer | Sell | 3,960 | $24.09 | $95K |
| Nov 10, 2025 | Cross ShawnChief Financial Officer | Sell | 12,060 | $22.09 | $266K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance